Beam Therapeutics BEAM Derivative, Gain (Loss) on Derivative, Net
Derivative, Gain (Loss) on Derivative, Net at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DerivativeGainLossOnDerivativeNet.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's derivative, gain (loss) on derivative, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's derivative, gain (loss) on derivative, net?
- Beam Therapeutics (BEAM) reported derivative, gain (loss) on derivative, net of $2.5M in Q1 2026.
- How has Beam Therapeutics's derivative, gain (loss) on derivative, net changed year-over-year?
- Beam Therapeutics's derivative, gain (loss) on derivative, net decreased by 21.9% year-over-year, from $3.2M to $2.5M.
- What is the long-term trend for Beam Therapeutics's derivative, gain (loss) on derivative, net?
- Over 3 years (2021 to 2025), Beam Therapeutics's derivative, gain (loss) on derivative, net has grown at a -42.6% compound annual growth rate (CAGR), from -$8.65M to $1.64M.
- What does derivative, gain (loss) on derivative, net mean?
- This metric represents the net change in fair value of derivative financial instruments held by the company. It reflects gains or losses arising from market fluctuations in underlying assets, liabilities, or hedging instruments. Investors monitor this to assess the impact of non-operating financial volatility on the company's bottom line.